Technical Articles

EphA2 is a tyrosine kinase receptor, so using tyrosine kinase inhibitors (TKIs) to inhibit the kinase activity of EphA2 is a potential therapeutic strategy. The multiple signaling pathways and non-kinase-dependent functions of EphA2 make targeted therapy complicated, and appropriate treatment methods need to be selected according to different tumor types and environments.